Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Stromal cell expression of caveolin-1 predicts outcome in breast cancer.

Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuello-Carrión FD, Gago FE, Anderson RL.

Am J Pathol. 2009 Jun;174(6):2035-43. doi: 10.2353/ajpath.2009.080924.

2.

An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.

Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP.

Am J Pathol. 2009 Jun;174(6):2023-34. doi: 10.2353/ajpath.2009.080873.

3.

Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.

Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP.

Clin Breast Cancer. 2004 Jun;5(2):105-16. Review.

PMID:
15245613
4.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005.

PMID:
19695680
5.

Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients.

Florena AM, Tripodo C, Guarnotta C, Ingrao S, Porcasi R, Martorana A, Lo Bosco G, Cabibi D, Franco V.

Pathobiology. 2007;74(6):317-22.

PMID:
18087195
6.

Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.

Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ.

Breast Cancer Res Treat. 2007 Nov;106(1):39-47.

PMID:
17221153
7.

Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.

González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ.

Hum Pathol. 2009 Sep;40(9):1224-33. doi: 10.1016/j.humpath.2008.12.022.

PMID:
19439346
8.

c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.

Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F.

Tumori. 2006 Jul-Aug;92(4):311-7.

PMID:
17036522
9.

Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.

Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2010 Aug;123(1):97-108. doi: 10.1007/s10549-009-0619-3.

PMID:
19911270
10.

Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.

Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, Sotgia F, Brody JR, Mitchell EP, Lisanti MP.

Cancer Biol Ther. 2010 Jul 15;10(2):135-43.

11.

Prostate-specific antigen value as a marker in breast cancer.

Narita D, Cimpean AM, Anghel A, Raica M.

Neoplasma. 2006;53(2):161-7.

PMID:
16575473
12.

Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.

Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.

Clin Cancer Res. 2003 Nov 1;9(14):5313-7.

13.

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.

Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y.

Breast Cancer Res. 2008;10(2):R35. doi: 10.1186/bcr1998.

14.

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.

Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD.

Clin Cancer Res. 2004 Mar 1;10(5):1706-16.

15.

The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M.

Breast Cancer Res Treat. 2006 Jun;97(3):275-83.

PMID:
16344916
16.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74.

PMID:
18045647
17.

Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.

Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES; Korean Breast Cancer Society..

Breast Cancer Res Treat. 2010 Aug;123(1):177-87. doi: 10.1007/s10549-010-0998-5.

PMID:
20574671
18.

Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.

Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS.

Mod Pathol. 2000 May;13(5):542-7.

19.

Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters.

Nakopoulou LL, Tsitsimelis D, Lazaris AC, Tzonou A, Gakiopoulou H, Dicoglou CC, Davaris PS.

Cancer Detect Prev. 1999;23(4):297-308.

PMID:
10403901
20.

Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.

Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E.

Clin Cancer Res. 2006 Nov 1;12(21):6359-66.

Items per page

Supplemental Content

Support Center